Imagenetix Inc is engaged in developing, formulating licensing and selling over-the-counter, natural-based nutritional supplements. Its products include Celadrin, a product formulation for joint health; and Periodyne a periodontal product.
| Website: | www.imagenetix.net |
| Email: | dsr@wwbcn.com |
| Main Phone: | +1 858 674-8455 |
| Address: | 10845 Rancho Bernardo Road |
| Address 2: | Suite 105 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92127 |
| Exchange: | OTO |
| Employees: | 5 |
| NAICS: | Pharmaceutical P |
| Last Price 0.0026 | Change $ 0.0001 | Change % 4.00 | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open 0.0026 | High 0.0026 | Low 0.0026 | Prev Close 0.0025 |
| Last Trade | Volume 10,000 | 52 Wk Hi 0.05 | 52 Wk Low 0.0025 |
| Market Cap 73,900 | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 28,422,955.00 | EPS (TTM) -0.01 | PE Ratio N/A | Exchange OTCPK |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 15-15D | Certification of Termination of Registration | 1 | 2015-11-02 |
| 8-K | Report of unscheduled material events or corporate changes. | 2 | 2015-11-02 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2015-10-21 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 32 | 2015-08-14 |
| 10-K | Annual report with a comprehensive overview of the company | 57 | 2015-06-29 |
| 8-K | Report of unscheduled material events or corporate changes. | 2 | 2015-06-16 |
| 10-QT | Quarterly transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act | 25 | 2015-02-13 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2014-11-20 |
| 10-QT | Quarterly transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act | 23 | 2014-11-19 |
| NT 10-Q | Notification that form 10-Q will be submitted late | 2 | 2014-11-14 |
© 2017 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
